Algernon Pharmaceuticals Expands Its Research Program to Include Idiopathic Pulmonary Fibrosis
25 févr. 2019 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...